Showing results (81-90 of 276) with videos related to
Sort By:
Pageof 28
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 15, 2014
Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5)Günter Emons, Grigor Gorchev, Philipp Harter, et al.Communications Biology|October 1, 2025
Long non-coding RNAs as a biomarker for homologous recombination deficiency and parp inhibitor sensitivity in high-grade serous ovarian cancersKai Doberstein, Johannes Panther, Eric Hahnen, et al.Gynecologic Oncology|October 15, 2023
Low anterior resection syndrome and its impact on quality of life of ovarian carcinoma patients: A prospective longitudinal studyMajdi Imterat, Gudrun Gebers, Florian Heitz, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 31, 2018
Uterine and Tubal Lavage for Earlier Cancer Detection Using an Innovative Catheter: A Feasibility and Safety StudyElisabeth Maritschnegg, Florian Heitz, Nina Pecha, et al.Gynecologic Oncology|January 26, 2016
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabaseJacek P Grabowski, Philipp Harter, Florian Heitz, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 19, 2025
Survival impact and prognostic factors of secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a systematic review and trial-level meta-analysisJi Hyun Kim, Myong Cheol Lim, Eun Taeg Kim, et al.Archives of Gynecology and Obstetrics|March 12, 2025
Intergroup-statement: statement of the german ovarian cancer commission, the North-Eastern German Society of gynecological Oncology (NOGGO), AGO Austria and AGO Swiss regarding the use of homologous repair deficiency (HRD) assays in advanced ovarian cancerLukas Chinczewski, Philipp Harter, Lukas Heukamp, et al.Archives of Gynecology and Obstetrics|February 15, 2020
Sentinel lymph node mapping with fluorescent and radioactive tracers in vulvar cancer patientsSonia Prader, Andreas du Bois, Philipp Harter, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for high-grade undifferentiated sarcomas of the uterusPatricia Pautier, Eun Ji Nam, Diane M Provencher, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2013
Randomized, phase II, placebo-controlled, double-blind study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment followed by maintenance treatment in advanced ovarian cancerIgnace B Vergote, Radoslav Chekerov, Frederic Amant, et al.Pageof 28